CellCept and Myfortic Receive Renewed FDA Warning

Roche’s CellCept and Novartis’ Myfortic have received renewed warnings from the FDA after miscarriages have been reported in organ transplant patients who’ve used the drugs. The initial FDA warning came last October after initial reports of miscarriages and birth defects in pregnant women. According to the FDA, the renewed warning occurred because the federal agency was concerned that doctors had not been aware of the initial warning.
The drugs are used to suppress the immune system in order to avoid organ transplant rejection.